January 25, 2001 Ms. Anna Hall Director of Business Development Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990 RE: AMENDMENT NO. 5 TO THE INTERMUNE/GENENTECH LICENSE AGREEMENT Dear Ms. Hall:
QuickLinks -- Click here to rapidly navigate through this document
January 25, 2001
Ms. ▇▇▇▇
▇▇▇▇
Director of Business Development
Genentech, Inc.
▇ ▇▇▇ ▇▇▇
▇▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇ ▇▇▇▇▇-▇▇▇▇
RE: AMENDMENT NO. 5 TO THE INTERMUNE/GENENTECH LICENSE AGREEMENT
Dear ▇▇. ▇▇▇▇:
Please consider this document as Amendment No. 5 to that certain License Agreement for Interferon Gamma, dated May 5, 1998; as amended on December 26, 1998; January 15, 1999; April 27, 1999; and June 23, 2000 (collectively, the "Agreement"), between INTERMUNE PHARMACEUTICALS, INC. and GENENTECH, INC. (collectively, the "Parties").
1. The Parties agree that the first sentence of Section 2.2(b) of the Agreement is hereby terminated in its entirety and amended and superseded as follows:
- "(b)
- Use of the ▇▇▇▇. In using the Actimmune ▇▇▇▇, InterMune shall display said ▇▇▇▇ with either the first letter in uppercase (i.e., Actimmune) or all letters in uppercase (i.e., ACTIMMUNE)."
2. All other sections and exhibits of the Agreement remain unchanged.
3. This Amendment No. 5 to the Agreement is made effective as of January 25, 2001.
IN WITNESS THEREOF, the parties have executed this Amendment No. 5 to the Agreement as of the date set forth below.
| INTERMUNE PHARMACEUTICALS, INC. | GENENTECH, INC. | |||||
By |
/s/ ▇▇▇▇ ▇. ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇. Vice President of Corporate Development |
By |
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ |
|||
Print Name |
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ |
|||||
Title |
VP BUSINESS DEVELOPMENT |
|||||
Date |
January 25, 2001 |
Date |
4/5/01 |
|||